Special Drug Use-Results Survey of Coralan

Special Drug Use-Results Survey of Coralan [chronic cardiac failure with sinus rhythm and baseline resting heart rate >=75 beats/min Limited to patients under standard of care for chronic cardiac failure, including beta-blockers ]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080225341

Enrollment

600

Registered

2020-08-24

Start date

2020-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

investigational material(s) Generic name etc : Coralan Tablets 2.5 mg Coralan Tablets 5 mg Coralan Tablets 7.5 mg INN of investigational material : Ivabradine Therapeutic category code : 219 Other car

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients will be registered as subjects in this survey if they are chronic heart failure patients with sinus rhythm and a resting heart rate of >=75 bpm at the initiation of the treatment who are receiving the standard of care for chronic heart failure, including beta-blockers, which is specified as indication of the drug, and they have no previous history of treatment with the drug.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety Safety items : Occurrence of adverse drug reactions set as safety specifications, factors considered to influence the safety Efficacy items : Resting heart rate, pulse rate, NYHA heart function class, left ventricular ejection fraction, left ventricular end-systolic volume, left ventricular end-diastolic volume, subjective symptoms (shortness of breath, swelling, frequent fatigue, decreased appetite, insomnia), BNP, NT-proBNP, factors considered to influence the efficacy	—

Measure

Time frame

safety Safety items : Occurrence of adverse drug reactions set as safety specifications, factors considered to influence the safety Efficacy items : Resting heart rate, pulse rate, NYHA heart function class, left ventricular ejection fraction, left ventricular end-systolic volume, left ventricular end-diastolic volume, subjective symptoms (shortness of breath, swelling, frequent fatigue, decreased appetite, insomnia), BNP, NT-proBNP, factors considered to influence the efficacy

—

Countries

Japan

Contacts

Public ContactTakafumi Nakao

ONO PHARMACEUTICAL CO.,LTD.

pms_contact_ml@ono-pharma.com+81-662225501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026